X-ray therapy also results in a decrease in goiter size, and frequently in myxedema, but should not be used because of the possible induction of thyroid carcinoma
Patients should be encouraged to report any adverse effects, changes in symptoms, or difficulties with medication adherence, while healthcare providers should provide ongoing support, education, and guidance to empower patients to manage their condition effectively
Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimers disease
The precise role of MoMFs in ALD remains incompletely understood
The kit provides a reusable, ergonomic pen, pre-mixed cartridges, sterile needle tips for safety, and a durable carry case for organisation
[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated
